Anamol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anamol

Quick Facts

Property Description
Active Ingredient Acetaminophen (Paracetamol)
Pharmacological Class Analgesic and Antipyretic
Key Function Pain relief and fever reduction
Typical Forms Tablet, Capsule, Oral Suspension
Origin Synthetic Organic Compound

Identity, Composition, and Pharmacological Class

Anamol is a medicinal preparation containing Acetaminophen, the compound internationally recognized as Paracetamol, as its active ingredient. This substance is formally classified as a Non-Opioid Analgesic and Antipyretic, defining its established function to mitigate discomfort and reduce elevated body temperature. Acetaminophen is a synthetic organic compound, meticulously manufactured for chemical consistency. Its chemical identity is defined by the structure N-(4-hydroxyphenyl)acetamide. Its designation as a Non-Opioid Analgesic confirms that its mechanism is distinct from opioid-based medications, positioning it as a fundamental Over-The-Counter (OTC) agent for systemic symptom management.

Pharmaceutical Forms and General Therapeutic Purpose

The single-ingredient product identity of Anamol allows its formulation into diverse pharmaceutical preparations, ensuring suitability for various patient needs and routes of administration. Common forms include the oral tablet and capsule, the liquid oral suspension often targeted at pediatric patients, and the specialized intravenous (IV) solution for clinical use. The general therapeutic purpose of this preparation is the provision of analgesia (pain relief) and antipyresis (fever reduction). The substance is utilized for the symptomatic relief of mild to moderate pain and fever. This sustained clinical recognition establishes the preparation's importance for general, short-term symptom relief.

What side effects are possible with Anamol?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of medicines like Anamol according to the nature and frequency of adverse reactions, as well as specific limitations for use.

Adverse Reaction Scope Official Regulatory Classification
Common (Reported in ge 1/100 to <1/10 patients) Nausea, vomiting, abdominal pain, diarrhea, constipation, headache, insomnia.
Serious Adverse Reactions Acute liver failure/hepatotoxicity, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP).
System-Organ Classes Involved Gastrointestinal Disorders, Nervous System Disorders, Hepato-biliary Disorders, and Skin and Subcutaneous Tissue Disorders.

Safety-Related Restrictions and Limitations

  • Hepatic Safety: The medicine is formally contraindicated or requires extreme caution and dose adjustment in patients with severe liver disease or active liver impairment, and in individuals with chronic, heavy alcohol use due to the risk of severe hepatotoxicity.
  • Skin Reactions: The potential for rare but life-threatening serious skin reactions (SJS, TEN, AGEP) is officially documented, necessitating immediate cessation of the medicine upon the first appearance of rash or other signs of hypersensitivity.
  • Population-Specific Considerations: Caution and dose adjustment are required for use in patients with pre-existing kidney dysfunction (renal impairment). Use in children must adhere strictly to weight-based dosing and prescribed intervals, avoiding combination with other products containing the same active ingredient to prevent overdose.

Regulatory Safety Summary The official safety documents structure the risk understanding by defining Serious Adverse Reactions (e.g., liver failure, severe skin reactions) as the most critical potential outcomes requiring strict precautions and immediate clinical review. Common adverse effects, such as gastrointestinal upset and headache, represent expected, frequent, but generally less severe issues. Continuous post-marketing surveillance is mandated to ensure the medicine's documented safety profile is dynamically maintained based on global usage experience.

Overdose and Emergency Response

The official regulatory profile for an overdose of Anamol (Acetaminophen/Paracetamol) highlights the risk of delayed organ toxicity. Initial signs of overdose may be non-specific, including nausea, vomiting, pallor, and diaphoresis. Due to the possibility of serious, delayed symptoms, immediate medical attention must be sought for any suspected ingestion exceeding the recommended maximum dose, even if the person feels well.

The primary severe outcome documented in regulatory labeling is acute liver failure due to hepatic necrosis, which is capable of causing death. Progression may also involve acute renal tubular necrosis. The established emergency treatment is the time-sensitive administration of the antidote N-acetylcysteine (NAC), which provides maximum benefit when given early.

Clinical management, as required by official protocols, involves urgent hospital monitoring, including the measurement of plasma acetaminophen concentration and continuous monitoring of hepatic and renal function. Regulatory documents also note specific risk factors for enhanced liver toxicity, such as conditions associated with chronic alcoholism or glutathione depletion. This regulatory structure is centered on mandatory, rapid intervention.

Therapeutic Uses of Anamol

Anamol is commonly used to help with symptoms related to physical discomfort, applied across domains where additional symptomatic support is needed. The therapeutic use of Anamol is considered relevant for the temporary relief of pain and fever. This medication is relevant for easing mild to moderate discomfort, which includes headache, muscular aches, backache, toothache, and cyclical discomfort like menstrual cramps.

This supportive relief is often applied during phases when symptoms become more noticeable, such as acute episodes associated with colds and flu. When used for fever, Anamol plays a role in managing symptoms related to systemic imbalance, specifically helping to address the symptom of an elevated body temperature. “It is a fundamental approach to providing short-term symptomatic assistance when pain or fever interferes with daily comfort.” This function primarily supports the patient by easing the overall symptom burden and may assist with maintaining a sense of stability during these symptomatic phases.

Quick Fact: Key Focus: Supportive Relief for Mild to Moderate Pain and Fever

Eligibility and Restrictions for Use

Population Eligibility and Restrictions

The eligibility profile for Anamol (Acetaminophen/Paracetamol) is defined by regulatory documents that specify who is permitted to use the medicine and who must be excluded.

Absolute Contraindications (Non-Eligibility)

Anamol is strictly contraindicated and must not be used by individuals with a known hypersensitivity or allergy to the active ingredient or any of the formulation's components. Use is also prohibited in patients diagnosed with severe active liver disease or severe hepatic impairment. To prevent accidental overdose and severe liver injury, the medicine is also contraindicated if the individual is concurrently taking any other medicinal product that contains acetaminophen.

Age-Group and Organ Function Restrictions

Use is generally established for adults, adolescents, and children aged two years and older. While older adults typically have no overall safety differences, eligibility is restricted for patients with severe renal impairment, which may necessitate conditional use and longer dosing intervals. Caution is also advised for individuals with chronic alcohol misuse or chronic malnutrition, as these factors increase the risk of hepatotoxicity.

Reproductive Status Eligibility

Official labeling confirms that the medicine is generally compatible with breastfeeding. For pregnant individuals, use is permitted only when considered clearly necessary, and must be strictly limited to the lowest effective dose for the shortest duration.

What should I know about interactions with other medicines?

The official regulatory profile for Anamol (Acetaminophen/Paracetamol) details interactions that modify plasma concentration, alter metabolism, and affect the pharmacodynamic actions of other co-administered substances.

Documented Drug-Drug Interactions

The co-administration of Anamol with any other product containing acetaminophen is a formal contraindication to avoid the risk of severe hepatic injury due to dose exceeding.

Interaction effects often involve the alteration of clearance. Probenecid is documented to reduce the clearance of Anamol, which can increase its systemic exposure. Conversely, liver enzyme inducers (e.g., Phenytoin, Carbamazepine, Rifampicine) may increase Anamol's metabolism, potentially heightening the risk of hepatotoxicity.

Timing and Pharmacodynamic Constraints

The absorption of Anamol is reduced by Cholestyramine, necessitating a separation of administration by at least one hour before or four hours after the substance. Anamol is documented to reduce the clearance of Busulfan, requiring avoidance for a specified period prior to and during Busulfan infusion.

Prolonged, regular daily use of Anamol enhances the anticoagulant effect of Warfarin and other coumarins, which is associated with an increased risk of bleeding. The risk of severe liver damage is officially noted for individuals consuming three or more alcoholic drinks every day while using this product.

Mechanism of Action

Central Regulation of Body Temperature and Prostaglandins

This domain involves the conditional, non-competitive inhibition of Cyclooxygenase (COX) enzymes primarily within the Central Nervous System (CNS). This action selectively reduces the synthesis of Prostaglandin E2 ( PGE2) in the hypothalamus, effectively engaging a mechanism that modifies the hypothalamic thermoregulatory set point.


Modulation of Central Anti-Nociceptive Pathways

Anamol utilizes an active metabolite ( AM404) to influence specific central receptors, including TRPV1 and CB1 receptors, which are key components of the endogenous nociceptive inhibitory pathways. This mechanism facilitates the natural descending inhibitory pathways, influencing the transmission of ascending nociceptive signals.


Mechanistic Specificity and Peripheral Limitation

The drug’s COX inhibition mechanism is highly sensitive to the local environment, specifically requiring low peroxide tone to be effective. Since this low peroxide concentration is generally absent in acute peripheral inflammation, the mechanism is constrained, leading to a negligible effect on peripheral inflammation and no detectable antiplatelet activity.

Dosage and Administration Information

How Anamol is Used: Official Administration Guidelines

This section summarizes the official usage instructions for Anamol (Acetaminophen/Paracetamol), detailing the route, dosing, frequency, and population-specific rules.


Administration Scope

Category Official Instructions
Route of administration Oral (tablets, solutions), Intravenous (IV) solution, and Rectal (suppositories).
Dosing schedule (Adults ≥ 50 kg) Standard single dose is typically 650 mg or 1000 mg (1 g). The total dose from all routes must not exceed 4000 mg (4 g) in any 24-hour period.
Frequency and Interval Dosing must be repeated no more frequently than every 4 to 6 hours as needed. The minimum interval between any two administrations is 4 hours.
Preparation requirements Oral solutions or suspensions must be measured using the dosing device provided. Modified-release forms, if available, must typically be swallowed whole and not chewed or crushed.
Age-group administration rules Pediatric dosing is strictly weight-based (e.g., 10 to 15 mg/kg per dose). Dose adjustments (e.g., reduction in total daily limit) are necessary for patients with documented hepatic impairment.
Course duration For self-care, administration is limited to no more than 10 days for pain or 3 days for fever, unless otherwise advised.

Connection to the Overall Use Protocol

Official instructions establish a rigid framework for the medicine’s correct use by strictly defining the appropriate routes of delivery and setting explicit numerical boundaries for the maximum total daily intake. This protocol is conditioned by mandatory time intervals between administrations and required dose modifications for specific patient populations, ensuring procedural adherence.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anamol


Evidence for Use in Acute Pain Relief

Research examined Anamol for outcomes related to physical discomfort mainly through short-term Randomized Controlled Trials (RCTs). These studies primarily focused on research exploring short-term symptom changes in acute episodes, such as headache or post-operative pain. Researchers studied for changes in pain intensity over short intervals, often measuring patient-reported outcomes describing perceived discomfort within the first few hours. Findings were mixed when comparing different doses, and the evidence quality varies across studies based on the specific acute pain models used. Comparative evidence is lacking against other active compounds studied in similar research, and follow-up durations were limited for continuous use extending beyond a few days.


Evidence for Use in Fever Reduction (Antipyresis)

The evidence base has been evaluated in numerous RCTs, focusing on outcomes related to systemic or functional imbalance by measuring body temperature change. Research examined both pediatric patients and adults with fever. Data show patterns related to changes in elevated body temperature that were measured following administration. What is known is largely based on research exploring short-term symptom changes, and long-term effects are not fully established regarding the use of this medicine for fever that persists or recurs.


Evidence for Use in Chronic Pain Conditions

The research structure for Anamol in conditions marked by functional limitations, such as osteoarthritis, includes Systematic Reviews and intermediate-term continuous dosing trials. Studies examined patient-reported outcomes describing perceived discomfort over periods longer than those used for acute symptoms. In certain high-quality reviews, findings indicate that the observed changes in pain and function scores were minimal when compared to inactive treatments. Certainty remains low due to inconsistent findings and the small size of the observed effect. The follow-up durations were limited for a condition requiring long-term management.


Evidence in Special Populations and Uncertainties

Research was studied for pediatric patients specifically for fever management, where the evidence contributes to the broader evidence landscape. Conversely, for complex comorbidity-defined groups or older adults studied for chronic pain, evidence is limited. Consequently, long-term effects are not fully established regarding the use of this medicine over many months or years. Evidence is limited regarding the clinical relevance of findings for certain chronic pain conditions, and the data are still emerging regarding comparative outcomes against newer compounds.

Key Studies & References

  1. Acetaminophen Toxicity - StatPearls (Source for pharmacological class and identity)
  2. Paracetamol - N-(4-hydroxyphenyl)acetamide (Source for chemical identity)

Frequently Asked Questions (FAQ)

Common questions about Anamol (FAQ)


Q: Is Anamol the same kind of medicine as [similar generic drug name]?

Official classification documents describe Anamol as a non-opioid analgesic and antipyretic (a pain and fever reducer). Unlike some other over-the-counter pain relievers, it does not possess significant anti-inflammatory activity. This distinction is based on how its therapeutic action is officially defined.


Q: How long does it typically take to feel the effects of Anamol?

According to official product information, the onset of pain-relieving effects generally occurs within 30 to 60 minutes following oral administration. This expected time frame is part of the oral dose's established pharmacological profile.


Q: Are there any common foods or drinks that should be avoided while using Anamol?

Official regulatory documents focus on a specific interaction risk involving alcohol, particularly for individuals consuming three or more alcoholic drinks daily, due to the increased risk of liver issues. No common foods or drinks other than alcohol are listed as requiring avoidance in the mandatory regulatory warnings.


Q: Can Anamol affect laboratory blood tests?

Regulatory documents note that Anamol has the potential to interfere with the results of specific laboratory tests. This interference may affect tests that measure compounds like blood sugar (glucose) or certain indicators of kidney function. Official guidance notes that due to this potential for interference, healthcare providers should be made aware of the patient's use of this medicine prior to testing.


Q: What is the main difference between Anamol and other options for this condition?

Official descriptions note that Anamol (Acetaminophen) is distinct from Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a different class of pain reliever. Its primary action is limited to pain relief and fever reduction, with negligible effect on peripheral inflammation as defined by its specific mechanism.


Q: What does 'contraindication' mean in relation to Anamol?

In official drug documents, a contraindication is described as a condition or situation where the use of the medicine must be avoided because the potential for harm outweighs any potential benefit. For Anamol, official contraindications include a known allergy to the medicine or a diagnosis of severe active liver disease.


Q: Can Anamol be taken by people with a history of heart problems?

Official documents do not list a history of heart problems as an absolute contraindication for use. However, some research has examined the potential for regular, prolonged daily use to affect blood pressure in individuals who have pre-existing high blood pressure (hypertension).


Q: Are there special precautions for people who operate machinery while using Anamol?

Regulatory information typically includes warnings if a medicine causes effects like drowsiness or dizziness that could impair safe operation. Anamol's common side effects as documented in the label do not typically include sedation that would necessitate a mandatory machinery restriction.


Q: How is Anamol eliminated from the body?

The medicine is primarily metabolized in the liver, where it is converted into inactive compounds. These inactive compounds are then eliminated from the body, mostly through the kidneys (urinary excretion), according to the drug's official pharmacokinetic data.


Q: Do official documents mention Anamol's effect on driving ability?

Official documents will caution against driving or operating machinery if the medicine causes effects like dizziness or altered consciousness. Because Anamol's common side effects as documented in the label do not typically include sedation, a driving restriction is not routinely listed in the warnings.


Q: Is there a patient support program for Anamol?

While the drug itself is generally available over-the-counter and does not have a formal manufacturer support program, regulatory bodies support public education campaigns. These campaigns (e.g., "Know Your Dose") focus on the safe use and appropriate dosing of medicines containing the active ingredient.


Q: What are the main ingredients in Anamol besides the active component?

The full product labeling lists all ingredients, including the inactive ingredients (excipients) used to formulate the tablet, capsule, or liquid. The inactive ingredient list is included in the labeling for patients with known allergies or sensitivities.


Q: Does the effectiveness of Anamol change over time?

Official research summaries primarily focus on short-term use and note that long-term effects are not fully established regarding continuous use over many months or years. Regulatory statements generally do not indicate that efficacy decreases over a typical therapeutic duration.


Q: What is the difference between a side effect and an adverse event for Anamol?

In official regulatory documents, side effects generally refer to common, less severe, and expected effects that are observed frequently, such as a mild headache. Adverse reactions refer to any unwanted and unexpected event, often encompassing the most critical outcomes like severe liver failure or severe skin reactions.


Q: Do official sources list any dietary restrictions with Anamol?

Official regulatory documents indicate a specific interaction risk with alcohol, particularly for individuals who consume three or more alcoholic drinks daily. No additional broad dietary restrictions (i.e., specific foods) are mandated in the warnings.


Q: Is Anamol a short-acting or long-acting medication?

According to official product labeling, the standard dosing instructions define the required interval between doses as every 4 to 6 hours. This is the characteristic interval for a short-acting medication used for acute, temporary symptom relief.


Q: What are the specific signs of a serious interaction with Anamol?

For serious interactions involving blood thinning medications, patient-observable signs may include unusual bleeding or bruising. Signs of a rare but critical skin reaction (like SJS/TEN/AGEP) are officially documented as reddening of the skin, rash, or blisters, which are considered signs that require clinical review.


Q: Can I take Anamol if I have a history of seizures?

While Anamol itself is not typically associated with seizure risk, official interaction documents note that it may interact with certain Antiseizure Medications (ASMs). This is because Anamol can affect how these other medicines are metabolized (processed) in the liver.


Q: Does Anamol have different instructions for men and women?

Official administration guidelines and eligibility requirements are defined primarily by age, weight, and organ function (e.g., liver or kidney status). Regulatory documents do not contain gender-specific instructions for use in men and non-pregnant women.


How should Anamol be stored and disposed of?

How to Store and Dispose of Anamol?

The storage and disposal of Anamol (Acetaminophen/Paracetamol) must follow specific regulatory instructions to maintain product integrity and ensure safety.

Official Storage Requirements

Anamol must be stored at controlled room temperature, typically 20 C to 25 C. The product requires protection from environmental factors; it must be stored in its original container, kept tightly closed, and shielded from excessive moisture and strong light. It is explicitly stated that the medicine, particularly liquid forms, must not be frozen.

Disposal and Safety

For child safety, the product must always be kept out of the sight and reach of children. Disposal of unused or expired Anamol should be carried out according to local regulations, restricting disposal via wastewater. The official recommendation is to utilize authorized drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anamol found in:

A-Z Index: